Paclitaxel infusion

DRUG2 trials

Sponsors

Novartis Pharmaceuticals, GlaxoSmithKline

Conditions

Neoplasms, Breast

Phase 2

Lapatinib Combined With Paclitaxel For Patients With First-Line ErbB2-Amplified Metastatic Breast Cancer

CompletedNCT00356811

GlaxoSmithKlineNeoplasms, Breast

Start: 2006-05-31End: 2013-12-31Updated: 2014-07-21

Phase 3

Study In Women And Men With Metastatic Breast Cancer That Have Overexpression Of ErbB2

CompletedNCT00281658

Novartis PharmaceuticalsNeoplasms, Breast

Start: 2006-01-02End: 2021-11-23Updated: 2023-02-10

Related Papers

Association of phosphatase and tensin homolog low and phosphatidylinositol 3-kinase catalytic subunit alpha gene mutations on outcome in human epidermal growth factor receptor 2-positive metastatic breast cancer patients treated with first-line lapatinib plus paclitaxel or paclitaxel alone.

2014-07-2426 citations

Evaluation of pro-apoptotic BIM gene loss of function on lapatinib efficacy in patients with metastatic breast cancer (MBC) and in HER2-amplified cell lines.

Journal of Clinical Oncology2014-05-20